Ratings by Barclays (Geoff Meacham)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/3/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2024 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/3/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/9/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/27/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2023 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 1/3/2023 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2022 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/29/2022 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/7/2022 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 10/29/2021 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/6/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 4/30/2021 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 4/28/2021 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 2/12/2021 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 2/10/2021 | II-VI, Inc. | IIVI | Maintain | Overweight (N/A) |
|
Details | ||
| 1/26/2021 | II-VI, Inc. | IIVI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2020 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 11/6/2020 | II-VI, Inc. | IIVI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/30/2020 | Seagen | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2020 | Retrophin | RTRX | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/31/2020 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 7/14/2020 | Gritstone Oncology | GRTS | Maintain | Overweight (N/A) |
|
Details | ||
| 5/12/2020 | Genfit | GNFT | Downgrade | Equalweight (Overweight) |
22.00 (4.85) |
-77.95% | Details | |
| 5/1/2020 | Seattle Genetics | SGEN | Maintain | Equalweight (N/A) |
|
Details | ||
| 3/23/2020 | II-VI, Inc. | IIVI | New Coverage | Overweight (N/A) |
25.62 (41.95) |
63.74% | Details | |
| 2/25/2020 | Retrophin | RTRX | Downgrade | Equalweight (Overweight) |
17.28 (24.25) |
40.34% | Details | |
| 2/18/2020 | Seattle Genetics | SGEN | Downgrade | Equalweight (Overweight) |
118.22 (228.74) |
93.49% | Details | |
| 8/23/2019 | Retrophin | RTRX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2019 | Biogen | BIIB | Maintain | Equalweight (N/A) |
|
Details | ||
| 5/3/2019 | Acceleron Pharma | XLRN | Downgrade | Equalweight (Overweight) |
39.98 (178.75) |
347.1% | Details | |
| 5/3/2019 | Achillion Pharmaceuticals | ACHN | Downgrade | Underweight (Equalweight) |
2.91 (0.79) |
-72.85% | Details | |
| 5/3/2019 | Incyte | INCY | Downgrade | Equalweight (Overweight) |
78.91 (123.47) |
56.47% | Details | |
| 5/3/2019 | Celgene | CELG | Downgrade | Equalweight (Overweight) |
95.02 (108.24) |
13.91% | Details | |
| 5/3/2019 | Bristol-Myers Squibb Co. | BMY | Upgrade | Overweight (Equalweight) |
46.58 (66.05) |
41.8% | Details | |
| 4/22/2019 | Genfit | GNFT | New Coverage | Overweight (N/A) |
24.98 (4.85) |
-80.58% | Details | |
| 4/22/2019 | Retrophin | RTRX | New Coverage | Overweight (N/A) |
20.05 (24.25) |
20.95% | Details | |
| 3/19/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
| 3/11/2019 | CytomX Therapeutics | CTMX | New Coverage | Overweight (N/A) |
9.80 (7.30) |
-25.51% | Details | |
| 3/11/2019 | Kiniksa | KNSA | New Coverage | Overweight (N/A) |
16.18 (79.49) |
391.29% | Details | |
| 3/7/2019 | Moderna | MRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/5/2019 | Gossamer Bio Inc. | GOSS | New Coverage | Overweight (N/A) |
23.00 (0.14) |
-99.39% | Details | |
| 3/4/2019 | Alector Inc. | ALEC | New Coverage | Overweight (N/A) |
19.59 (2.21) |
-88.72% | Details | |
| 2/13/2019 | Myovant Sciences Ltd. | MYOV | Upgrade | Overweight (Equalweight) |
18.75 (26.98) |
43.89% | Details | |
| 2/7/2019 | Regeneron Pharma | REGN | Maintain | Underweight (N/A) |
|
Details | ||
| 1/2/2019 | Marina Biotech | MRNA | New Coverage | Overweight (N/A) |
15.27 (58.19) |
281.07% | Details | |
| 12/20/2018 | DBV Technologies S.A | DBVT | Downgrade | Equalweight (Overweight) |
14.69 (14.47) |
-1.5% | Details | |
| 11/7/2018 | Regeneron Pharma | REGN | Maintain | Underweight (Underweight) |
|
Details | ||
| 11/7/2018 | Ironwood Pharmaceuticals | IRWD | Maintain | Equalweight (N/A) |
|
Details | ||
| 10/26/2018 | Seattle Genetics | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2018 | Gilead Sciences | GILD | Maintain | Overweight (N/A) |
|
Details | ||
| 10/23/2018 | Gritstone bio | GRTS | New Coverage | Overweight (N/A) |
15.01 (0.03) |
-99.8% | Details | |
| 10/3/2018 | Seattle Genetics | SGEN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/28/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Overweight (N/A) |
|
Details | ||
| 9/18/2018 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 9/17/2018 | Bausch Health Companies | BHC | New Coverage | Overweight (N/A) |
22.35 (21.24) |
-4.97% | Details | |
| 9/7/2018 | Merck | MRK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/7/2018 | Eli Lilly | LLY | Maintain | Overweight (N/A) |
|
Details | ||
| 8/23/2018 | Pfizer | PFE | Maintain | Equalweight (N/A) |
|
Details |
